These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 31090669)

  • 1. A Systemic Inflammation Response Index Could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer.
    Pacheco-Barcia V; Mondéjar Solís R; France T; Asselah J; Donnay O; Zogopoulos G; Bouganim N; Guo K; Rogado J; Martin E; Alcindor T; Colomer R
    Pancreas; 2019; 48(5):e45-e47. PubMed ID: 31090669
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy.
    Qi Q; Zhuang L; Shen Y; Geng Y; Yu S; Chen H; Liu L; Meng Z; Wang P; Chen Z
    Cancer; 2016 Jul; 122(14):2158-67. PubMed ID: 27152949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Palliative chemotherapy for pancreatic cancer].
    Buscail L; Bournet B; Guimbaud R
    Gastroenterol Clin Biol; 2006 Jan; 30(1):106-9. PubMed ID: 16514388
    [No Abstract]   [Full Text] [Related]  

  • 4. A review of systemic therapy for advanced pancreatic cancer.
    El-Rayes BF; Philip PA
    Clin Adv Hematol Oncol; 2003 Jul; 1(7):430-4. PubMed ID: 16258429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Systemic chemotherapy for metastatic pancreatic cancer].
    Morizane C
    Nihon Shokakibyo Gakkai Zasshi; 2023; 120(8):651-657. PubMed ID: 37558411
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
    Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature.
    Caparello C; Vivaldi C; Fornaro L; Musettini G; Pasquini G; Catanese S; Masi G; Lencioni M; Falcone A; Vasile E
    Future Oncol; 2016 Apr; 12(7):901-8. PubMed ID: 26883177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer.
    Peixoto RD; Speers C; McGahan CE; Renouf DJ; Schaeffer DF; Kennecke HF
    Cancer Med; 2015 Aug; 4(8):1171-7. PubMed ID: 25891650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies.
    Abdel-Rahman O
    Clin Transl Oncol; 2019 Jun; 21(6):810-816. PubMed ID: 30465184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer.
    Geng Y; Qi Q; Sun M; Chen H; Wang P; Chen Z
    Eur J Surg Oncol; 2015 Nov; 41(11):1508-14. PubMed ID: 26343824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [FOLFIRINOX Combination Chemotherapy in Patients with Metastatic or Recurrent Pancreatic Cancer--A Single Institution Experience].
    Takeda Y; Katsura Y; Ohmura Y; Morimoto Y; Ishida T; Motoyama Y; Ohneda Y; Sato Y; Kuwahara R; Murakami K; Naito A; Kagawa Y; Okishiro M; Takeno A; Egawa C; Kato T; Tamura S
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2360-3. PubMed ID: 26805364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-generation inflammation-related scores are more effective than systemic inflammation ratios in predicting prognosis of patients with unresectable or metastatic pancreatic cancer receiving cytotoxic chemotherapy.
    Colloca GA; Venturino A; Guarneri D
    Med Oncol; 2018 Oct; 35(12):158. PubMed ID: 30374617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Locoregional and systemic therapy of advanced pancreatic carcinoma].
    Gebauer T; Ridwelski K; Fahlke J; Lippert H
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1344-7. PubMed ID: 9931877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
    Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.
    Brixi-Benmansour H; Jouve JL; Mitry E; Bonnetain F; Landi B; Hentic O; Bedenne L; Cadiot G
    Dig Liver Dis; 2011 Nov; 43(11):912-6. PubMed ID: 21831734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study.
    Safran H; Charpentier KP; Perez K; Mantripragada K; Miner T; DiPetrillo T; Kuritzky B; Apor E; Bishop K; Luppe D; Mitchell K; Rosati K
    Am J Clin Oncol; 2016 Dec; 39(6):619-622. PubMed ID: 26523444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic advances in metastatic pancreatic adenocarcinoma and related cancers: focus on evidence-based and sequenced approaches to survival extension in metastatic pancreatic adenocarcinoma.
    Bekaii-Saab T; Yu K; Lima CMSR; Wolin EM
    Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):1-16. PubMed ID: 30807558
    [No Abstract]   [Full Text] [Related]  

  • 18. Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis.
    Brunetti O; Aprile G; Marchetti P; Vasile E; Casadei Gardini A; Scartozzi M; Barni S; Delfanti S; De Vita F; Di Costanzo F; Milella M; Cella CA; Berardi R; Cataldo I; Scarpa A; Basile D; Mazzuca F; Graziano G; Argentiero A; Santini D; Reni M; Cascinu S; Silvestris N
    Pancreas; 2018 Jul; 47(6):759-771. PubMed ID: 29771769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Different Treatment Modalities on the Outcome of Pancreatic Cancer.
    Khan M; Ashraf MI; Syed AA; Hanif F
    J Coll Physicians Surg Pak; 2017 Aug; 27(8):470-474. PubMed ID: 28903837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.